Home › NDC Lookup › RxCUI directory › RxCUI 2375327

2 ML dupilumab 150 MG/ML Auto-Injector — RxCUI 2375327

RxNorm drug concept · Semantic clinical drug
RxCUI 2375327 Semantic clinical drug · SCD ● Current RxNorm concept 5 FDA products 10 package NDCs Snapshot Jul 14, 2026

This page is curated, coded, and maintained by

Compiled from public NLM RxNorm and FDA (openFDA NDC directory) data sources. Editorial policy

What you’re looking at: the standardized identity of one medicine, as the U.S. drug-data system sees it. Below — every FDA-listed product, package code, price benchmark, and billing code that maps to it.

🗂️ Key Facts

RxCUI2375327
Official name2 ML dupilumab 150 MG/ML Auto-Injector
Concept typeSemantic clinical drug (SCD)
RxNorm statusCurrent RxNorm concept
Also known asdupilumab 300 MG per 2 ML Auto-Injector; dupilumab 300 MG in 2 ML Auto-Injector
FDA products mapped5
Package NDCs mapped10
Reported Medicaid activity (SDUD)758,467 prescriptions · 52 state & territory Medicaid programs · latest period Q4 2025
RxNorm release07/06/2026
Snapshot dataJul 14, 2026

📖 Skip the Codes — Read It in Plain English.

Our pharmacist-built guide to Dupilumab Injection: what it is, how it’s used, side effects, and interactions.

📗 Our plain-language guide HelloPharmacist
  • Dupixent is used for a whole range of inflammatory conditions — not just one. It's approved for moderate-to-severe eczema (atopic dermatitis), certain types of asthma, chronic nasa...
  • Yes — Dupixent is a subcutaneous injection, meaning it goes just under the skin, and most people learn to do it at home. You inject it into your thigh, abdomen (not too close to th...
  • How do I take Dupixent, and can I do it at home?
  • The most common ones are redness or irritation at the injection site and eye problems — particularly conjunctivitis (pink eye) or eyelid inflammation, especially if you have eczema...
📖 Read our full Dupilumab Injection guide →

🕸️ Concept Web — How 2 ML dupilumab 150 MG/ML Auto-Injector Connects

One RxCUI never lives alone. Follow the path from the raw ingredient down to the exact strength-and-form concepts FDA products carry — every stop is a real RxNorm concept with its own identifier. Hover or focus any chip for what it means.
This page's concept 2 ML dupilumab 150 MG/ML Auto-Injector RxCUI 2375327

Every web starts here: one RxCUI, one fixed meaning in the RxNorm vocabulary.

  1. Ingredients 1

    The active substance itself — no strength, form, or brand attached yet.

    • Dupilumab 1876376
  2. Brand names 1

    The same medicine's trade names. A brand name alone says nothing about strength or form.

    • Dupixent 1876402
  3. Dose forms 6

    The ingredient poured into a form — tablet, solution, cream — still without one fixed strength.

    • Dupilumab Auto-Injector 2375326
    • Dupilumab Injectable Product 1876399
    • Dupilumab Auto-Injector [Dupixent] 2375328
    • Dupixent Injectable Product 1876405
    • Auto-Injector 1649570
    • Injectable Product 1151126
  4. Clinical & branded drugs 3

    Ingredient + strength + dose form. These are the concepts real FDA products actually carry.

Showing up to 8 concepts per family — 11 of 11 stored related concepts drawn.
These are official RxNorm vocabulary relationships — how concepts name and organize the same medicine. They do not establish therapeutic equivalence or substitutability: two concepts appearing in one web is never a statement that products can be swapped.

🔀 Generic ⇄ Brand Crosswalk

The same medicine has an unbranded (generic) identity and one or more brand-name identities — each with its own RxCUI. This is a naming relationship in RxNorm, not a statement that any two products are substitutable.

Generic (Clinical) Concepts

  • Dupilumab 150 MG/ML SCDC · 1876398
  • Dupilumab Auto-Injector SCDF · 2375326
  • Dupilumab Injectable Product SCDG · 1876399

Brand-Name Concepts

📦 FDA Products & Package NDCs

5 products · 10 package NDCs
10 package NDCs map to RxCUI 2375327 in the current snapshot — up to 50 per page. Each linked NDC opens its full package page.
Package NDC Package Brand / generic name Labeler Marketing start
00024-5911-02 2 SYRINGE, GLASS in 1 CARTON (0024-5911-02) / .67 mL in 1 S... Dupixent Sanofi-Aventis U.S. LLC 2021-10-20
00024-5911-20 2 SYRINGE, GLASS in 1 CARTON (0024-5911-20) / .67 mL in 1 S... Dupixent Sanofi-Aventis U.S. LLC 2021-10-20
00024-5914-01 2 SYRINGE, GLASS in 1 CARTON (0024-5914-01) / 2 mL in 1 SYR... Dupixent Sanofi-Aventis U.S. LLC 2017-03-28
00024-5914-02 2 SYRINGE, GLASS in 1 CARTON (0024-5914-02) / 2 mL in 1 SYR... Dupixent Sanofi-Aventis U.S. LLC 2018-07-01
00024-5915-02 2 SYRINGE, GLASS in 1 CARTON (0024-5915-02) / 2 mL in 1 SYR... Dupixent Sanofi-Aventis U.S. LLC 2020-06-19
00024-5915-20 2 SYRINGE, GLASS in 1 CARTON (0024-5915-20) / 2 mL in 1 SYR... Dupixent Sanofi-Aventis U.S. LLC 2020-06-19
00024-5918-01 2 SYRINGE, GLASS in 1 CARTON (0024-5918-01) / 1.14 mL in 1... Dupixent Sanofi-Aventis U.S. LLC 2018-10-19
00024-5918-02 2 SYRINGE, GLASS in 1 CARTON (0024-5918-02) / 1.14 mL in 1... Dupixent Sanofi-Aventis U.S. LLC 2018-10-19
00024-5919-02 2 SYRINGE, GLASS in 1 CARTON (0024-5919-02) / 1.14 mL in 1... Dupixent Sanofi-Aventis U.S. LLC 2021-06-14
00024-5919-20 2 SYRINGE, GLASS in 1 CARTON (0024-5919-20) / 1.14 mL in 1... Dupixent Sanofi-Aventis U.S. LLC 2021-06-14
Observed labelers: Sanofi-Aventis U.S. LLC (10) — this is the FDA-listed mapping footprint, not sales, inventory, availability, or market share.

🗃️ Sources & Limits

Atlas generation902fddb9-e9c1-4004-bf4c-dba4d51037c7
openFDA export observedJul 14, 2026
RxNorm release07/06/2026
Methodology2026-07-full-catalog-v1
  • A shared RxCUI does not prove interchangeability. Products mapped to the same concept are not thereby equivalent or substitutable — equivalence is a separate, product-level determination.
  • Listing here does not establish approval or coverage. Appearing in this snapshot is a data observation, not an FDA approval status or a payer coverage decision.
  • Missing data never means zero. A silent dataset (no price, no billing code, no utilization) means no observation — not that the real-world value is zero.
  • Counts describe the mapping footprint. Product, package, and labeler counts are the FDA-listed mapping footprint in this snapshot — not sales, inventory, availability, or market share.
This product uses publicly available data from the U.S. National Library of Medicine (NLM), National Institutes of Health, Department of Health and Human Services; NLM is not responsible for the product and does not endorse or recommend this or any other product.

Machine-readable JSON

Reference information about drug-concept identifiers and public regulatory data — not medical advice. Talk to your pharmacist or prescriber about your own medication.